Literature DB >> 17986112

Positron emission tomography in interstitial lung disease.

Samir Nusair1, Rina Rubinstein, Nanette M Freedman, Gail Amir, Naama R Bogot, Uzi Izhar, Raphael Breuer.   

Abstract

BACKGROUND AND OBJECTIVES: A high rate of glycolysis may reflect the inflammatory activity of interstitial lung disease (ILD). This prospective study investigated whether PET can distinguish IPF, a primarily fibrotic process, from other entities of ILD that have a marked inflammatory component.
METHODS: Twenty-one patients referred for surgical lung biopsy because of diffuse ILD underwent PET at the time of the lung biopsy. PET transmission scans were obtained after injecting (18)FDG intravenously. Regions of interest (ROI) were drawn on the lung images, and the standardized uptake value (SUV) was calculated for these ROI.
RESULTS: Of the 21 patients studied, 14 had IPF, four had non-specific interstitial pneumonia, and the remaining three patients each had respiratory bronchiolitis-ILD, sarcoidosis and Langerhan's cell histiocytosis. There was no statistically significant difference in the SUV between IPF patients and non-IPF patients (P = 0.26), although patients with IPF tended to have higher SUV. Radiographic changes tended to be more prominent in the lung bases in patients with IPF compared with non-IPF patients; however, the median ratio of SUV measured in the upper fields to the whole lungs in IPF patients was not significantly different compared with the median ratio in non-IPF patients (P = 0.31).
CONCLUSION: PET does not allow differentiation of IPF from a non-IPF diffuse interstitial pulmonary process.

Entities:  

Mesh:

Year:  2007        PMID: 17986112     DOI: 10.1111/j.1440-1843.2007.01143.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  7 in total

1.  The importance of correction for tissue fraction effects in lung PET: preliminary findings.

Authors:  Tryphon Lambrou; Ashley M Groves; Kjell Erlandsson; Nick Screaton; Raymondo Endozo; Thida Win; Joanna C Porter; Brian F Hutton
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-08-27       Impact factor: 9.236

Review 2.  Imaging Pulmonary Inflammation.

Authors:  Philip M Scherer; Delphine L Chen
Journal:  J Nucl Med       Date:  2016-09-01       Impact factor: 10.057

3.  Acute exacerbation of interstitial lung disease with lung cancer after surgery: evaluation with 2-[18]-fluoro-2-deoxy-D-glucose positron emission tomography.

Authors:  Tomohiro Maniwa; Masahiro Endo; Mitsuhiro Isaka; Kazuo Nakagawa; Yasuhisa Ohde; Takehiro Okumura; Haruhiko Kondo
Journal:  Surg Today       Date:  2013-09-05       Impact factor: 2.549

4.  18F-Fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible: implications for future clinical trials.

Authors:  Thida Win; Tryphon Lambrou; Brian F Hutton; Irfan Kayani; Nicholas J Screaton; Joanna C Porter; Toby M Maher; Raymondo Endozo; Robert I Shortman; Pauline Lukey; Ashley M Groves
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11-30       Impact factor: 9.236

5.  PET/CT and interstitial lung disease.

Authors:  Marcio Valente Yamada Sawamura; Ronaldo Adib Kairalla; Carlos Alberto Buchpigel
Journal:  J Bras Pneumol       Date:  2022-09-05       Impact factor: 2.800

6.  Childhood sarcoidosis: A rare but fascinating disorder.

Authors:  Avinash K Shetty; Abraham Gedalia
Journal:  Pediatr Rheumatol Online J       Date:  2008-09-23       Impact factor: 3.054

7.  Areas of normal pulmonary parenchyma on HRCT exhibit increased FDG PET signal in IPF patients.

Authors:  Thida Win; Benjamin A Thomas; Tryphon Lambrou; Brian F Hutton; Nicholas J Screaton; Joanna C Porter; Toby M Maher; Raymondo Endozo; Robert I Shortman; Asim Afaq; Pauline Lukey; Peter J Ell; Ashley M Groves
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-08-14       Impact factor: 9.236

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.